Stocx Research Club logo ×
Screener Research Unlisted Startup Funding

JB Chem & Pharma

₹1953.7 -5.5 | 0.3%

Market Cap ₹14996 Cr.

Stock P/E 37.1

P/B 6.2

Current Price ₹1953.7

Book Value ₹ 312.9

Face Value 2

52W High ₹2149.9

Dividend Yield 0.85%

52W Low ₹ 1342.2

Overview Inc. Year: 1976Industry: Pharmaceuticals & Drugs

J. B. Chemicals & Pharmaceuticals Ltd is an pharmaceutical company. It is an incorporated, research-orientated organization, which is focused on imparting products both in India and International markets. The Company manufactures and markets a range of herbal remedies, pharmaceutical formulations, active pharmaceutical ingredient (APIs). The Company is engaged in manufacturing distinctiveness merchandise that comprises various pharmaceutical dosage forms like drugs, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, liquids and pills. The Company's brands include Rantac (anti-peptic ulcerant), Cilacar (calcium channel blocker), Nicardia (calcium channel blocker) and Metrogyl (amoebicides).

Read More..

JB Chem & Pharma Share Price

| |

Volume
Price

Quarterly Price

Show Value Show %

JB Chem & Pharma Quarterly Results

#(Fig in Cr.) Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 444 548 528 606 593 601 625 785 809 793
Other Income 8 56 25 13 20 5 2 1 1 3
Total Income 452 604 554 619 613 605 627 786 811 796
Total Expenditure 333 377 405 442 466 473 500 612 625 618
Operating Profit 118 227 149 177 146 133 127 174 186 178
Interest 2 1 1 1 1 1 2 6 8 8
Depreciation 17 17 17 18 16 17 22 26 28 28
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 99 208 132 158 129 114 103 142 150 141
Provision for Tax 25 54 31 39 32 30 18 37 39 35
Profit After Tax 74 154 101 119 98 84 85 105 111 106
Adjustments -0 -0 -0 -0 -0 -0 -0 -0 0 0
Profit After Adjustments 74 154 101 119 98 84 85 105 111 106
Adjusted Earnings Per Share 9.6 19.9 13 15.4 12.6 10.9 11 13.6 14.4 13.7

JB Chem & Pharma Profit & Loss

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
Net Sales 802 866 1022 1144 1232 1368 1414 1643 1775 2043 2424 3012
Other Income 29 28 38 11 57 54 55 41 51 117 40 7
Total Income 831 894 1060 1155 1288 1422 1469 1685 1826 2159 2464 3020
Total Expenditure 702 760 874 964 1026 1140 1215 1337 1397 1486 1882 2355
Operating Profit 129 134 186 191 263 283 254 347 428 673 583 665
Interest 24 5 6 7 11 5 3 5 3 7 5 24
Depreciation 22 25 28 39 41 47 57 56 66 69 73 104
Exceptional Income / Expenses 761 0 -65 0 0 0 0 0 -10 0 0 0
Profit Before Tax 843 104 87 146 211 230 194 287 349 597 505 536
Provision for Tax 166 24 26 45 50 46 55 93 77 148 119 129
Profit After Tax 678 79 61 100 161 184 139 194 272 449 386 407
Adjustments 0 0 0 0 1 -0 -0 -1 -0 -1 -1 0
Profit After Adjustments 678 79 61 100 163 184 138 193 272 448 385 407
Adjusted Earnings Per Share 80 9.4 7.3 11.8 19.2 21.7 16.6 24.1 35.2 58 49.9 52.7

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 19% 14% 12% 12%
Operating Profit CAGR -13% 19% 16% 16%
PAT CAGR -14% 26% 16% -5%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 23% 63% 47% 39%
ROE Average 20% 22% 18% 20%
ROCE Average 25% 29% 24% 25%

JB Chem & Pharma Balance Sheet

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Shareholder's Funds 970 1020 1043 995 1184 1364 1442 1480 1435 1810 2134
Minority's Interest 0 0 0 0 2 2 3 3 3 4 4
Borrowings 13 7 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 27 33 31 32 31 27 46 65 63 72 79
Total Current Liabilities 188 239 276 460 797 693 736 782 516 687 852
Total Liabilities 1198 1300 1351 1487 2014 2086 2226 2329 2017 2572 3069
Fixed Assets 276 334 311 329 440 679 640 621 651 634 1277
Other Non-Current Assets 55 22 60 258 391 200 78 120 90 45 49
Total Current Assets 866 944 981 901 1182 1207 1509 1589 1276 1894 1743
Total Assets 1198 1300 1351 1487 2014 2086 2226 2329 2017 2572 3069

JB Chem & Pharma Cash Flow

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Opening Cash & Cash Equivalents 127 220 156 12 -5 7 -21 21 32 26 22
Cash Flow from Operating Activities 880 84 -14 127 140 201 123 194 276 315 170
Cash Flow from Investing Activities -261 -116 -142 -112 -28 -45 -21 -28 24 -231 2
Cash Flow from Financing Activities -526 -31 12 -1 -100 -184 -60 -156 -306 -87 -138
Net Cash Inflow / Outflow 93 -63 -144 13 13 -28 43 11 -6 -3 34
Closing Cash & Cash Equivalent 220 156 12 25 9 -21 21 32 26 22 57

JB Chem & Pharma Ratios

# Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Earnings Per Share (Rs) 80.03 9.38 7.26 11.84 19.16 21.7 16.55 24.11 35.2 57.96 49.86
CEPS(Rs) 82.68 12.29 10.56 16.4 23.87 27.31 23.42 31.11 43.83 66.92 59.35
DPS(Rs) 41 3 3 14 5 1 2 5 11 16.5 16.5
Book NAV/Share(Rs) 113.34 119.21 123.07 117.31 139.57 160.77 172.5 184.47 185.75 234.17 268.04
Core EBITDA Margin(%) 12.4 12.05 14.33 15.54 16.73 16.72 14.09 18.61 21.28 27.23 22.38
EBIT Margin(%) 107.19 12.42 9.03 13.15 17.98 17.2 13.97 17.75 19.84 29.58 21.04
Pre Tax Margin(%) 104.22 11.82 8.45 12.56 17.12 16.8 13.72 17.47 19.66 29.22 20.83
PAT Margin (%) 83.77 9.06 5.95 8.66 13.09 13.48 9.81 11.8 15.35 21.96 15.92
Cash Profit Margin (%) 86.54 11.88 8.65 12 16.44 16.93 13.84 15.19 19.09 25.32 18.92
ROA(%) 61.71 6.36 4.64 7.08 9.21 8.99 6.43 8.52 12.53 19.55 13.69
ROE(%) 82.49 8.07 5.99 9.86 14.8 14.48 9.89 13.28 18.69 27.64 19.89
ROCE(%) 92.09 10.41 8.5 13.49 17.72 16.87 13.7 19.59 23.71 36.53 25.48
Receivable days 108.62 68.16 75.3 78.41 79.28 71.84 73.15 67.63 67.22 65.62 71.12
Inventory Days 47.97 42.8 42.16 44.83 50.12 51.77 53.43 50.81 53.31 55.59 57.02
Payable days 49.78 47.94 70.5 73.91 62.53 62.76 70.44 69.69 82.55 92.33 89.07
PER(x) 0.76 7.84 17.68 16.9 13.01 15.99 18.68 14.91 14.44 21.63 31.59
Price/Book(x) 0.54 0.62 1.04 1.71 1.79 2.16 1.79 1.95 2.74 5.35 5.88
Dividend Yield(%) 67.1 4.08 2.34 7 2 0.29 0.65 1.39 2.16 1.32 1.05
EV/Net Sales(x) 0.46 0.6 1.14 1.57 1.86 2.18 1.83 1.75 2.21 4.74 5.01
EV/Core EBITDA(x) 2.85 3.87 6.29 9.42 8.74 10.54 10.15 8.28 9.17 14.4 20.84
Net Sales Growth(%) -9.98 8.01 17.98 11.97 7.64 11.1 3.32 16.23 8 15.09 18.69
EBIT Growth(%) 393.63 -87.45 -14.22 63.18 45.34 6.26 -16.09 47.71 20.75 71.55 -15.58
PAT Growth(%) 386.57 -88.28 -22.59 63.27 60.59 14.37 -24.77 39.83 40.43 64.66 -13.93
EPS Growth(%) 385.48 -88.28 -22.61 63.12 61.87 13.24 -23.72 45.66 45.99 64.66 -13.98
Debt/Equity(x) 0.07 0.05 0.09 0.13 0.16 0.04 0.02 0.02 0.02 0.02 0.01
Current Ratio(x) 4.6 3.94 3.55 1.96 1.48 1.74 2.05 2.03 2.47 2.76 2.05
Quick Ratio(x) 4.06 3.53 3.06 1.63 1.25 1.45 1.76 1.72 1.94 2.25 1.56
Interest Cover(x) 36.1 20.61 15.74 22.33 20.8 43.81 56.54 62.74 108.09 83.43 99.6
Total Debt/Mcap(x) 0.14 0.08 0.09 0.08 0.09 0.02 0.01 0.01 0.01 0 0

JB Chem & Pharma Shareholding Pattern

# Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Promoter 55.91 55.91 55.91 55.91 55.91 54 54 54 53.96 53.95
FII 7.25 7.87 7.54 8.37 8.74 9.12 9.22 8.85 8.66 8.8
DII 12.38 13.91 13.17 13.13 15.24 16.26 16.89 17.8 18.48 18.54
Public 24.47 22.31 23.38 22.58 20.12 20.62 19.89 19.35 18.91 18.71
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

JB Chem & Pharma News